While the FTSE 100 powers higher, Wall Street remains contained following its rebound earlier in the week, says Chris ...

Schneider Electric, today announced continued progress toward decarbonization for the pharmaceutical and healthcare sectors.

Yet GSK is clearly healing from its multiple comorbidities — the worst of which was the (now largely resolved) legal overhang related to heartburn medicine Zantac. Chief executive Emma Walmsley also ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

AstraZeneca continued to see strong growth in 2024 on the back of a series of positive trials, as well as a solid pipeline of ...

GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I ...

Harvey Jones hails the brilliant long-term performance of the AstraZeneca share price, but wonders whether the FTSE 100's ...

Swiss biotech BioVersys, which develops treatments for serious infections caused by drug resistant bacteria, has completed its initial public offering with an implied market valuation of 213 million ...

Chief executive Emma Walmsley said ministers must work with the sector to boost investment amid growing concerns about doing ...

Latest forecasts from the Office for Budget Responsibility (OBR) are thought to show that almost all the headroom has been ...

A task force has been set up to look into how to spend a £2m GSK legacy as the pharmaceutical giant closes its doors in Ulverston. Giles ...

The stock market extended its winning streak on Wednesday, closing firmer as investors seemed to have already priced in the ...